In 2017, the FDA approved the first cellular therapy for cancer, a living drug called Kymriah, developed at Penn by Dr. Carl June. Learn more about the significance of this new method of therapy and other revolutionary research being conducted at Penn.

Abramson Cancer Center's Pancreatic Research Center, led by Dr. Ben Stranger, is revolutionizing the way this disease is treated. Learn more about pancreatic cancer clinical trials at Penn and why there is now hope for all stages.

Dr. Aggarwal and the rest of the team at Penn are transforming the way lung cancer is treated. Learn more about their research and how new drugs are helping patients.

Learn more about Dr. Julia Tchou's new approach to treating patients with early stage breast cancer, which combines immunotherapy and radiation.

Looking at a tumor’s genetic information can provide a clearer picture of a patient’s unique condition and how to best treat it.

Danielle’s genetic testing journey changed her life. Read how she’s taken charge of her health to get ahead of her family’s history of pancreatic cancer.

Medical oncologist Dr. Mark H. O’Hara explains how research on innovative immunotherapy therapies at Penn may offer hope to current and future pancreatic cancer patients.

When Denise found herself diagnosed with cancer for a second time in her young life, she found comfort in the many cancer treatment and fertility preservation options available to her at Penn Medicine. Read about her journey and the research studies that are giving her hope for her future.

A new research initiative being pioneered at Penn’s Basser Center, the BRCA Founder Outreach Study (BFOR study) is dedicated to developing and integrating new methods of genetic testing into medical care.

With advancements in immunotherapy, radiation therapy and surgical resection, Penn Medicine is making progress towards a life-extending treatment for the aggressive brain cancer, glioblastoma.